

REIMAGINE WHAT'S POSSIBLE



Treatment Expectations Guide:

Preparing for your journey ahead

AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg

Avmapki Fakzynja Co-Pack is the first FDA-approved prescription medicine specifically for adults who have low-grade serous ovarian cancer (LGSOC) that has come back (recurrent), and LGSOC with an abnormal *KRAS* gene, and previously been treated with medicine for their cancer.

It is not known if Avmapki Fakzynja Co-Pack is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Avmapki Fakzynja Co-Pack may cause serious side effects, including eye problems, severe skin reactions, liver problems, and muscle problems such as rhabdomyolysis. These are not all the possible side effects of Avmapki Fakzynja Co-Pack. Call your doctor for medical advice about side effects.

Please see additional Important Safety Information throughout this brochure and discuss with your doctor. Click here for full [Prescribing Information](#) and [Patient Information](#).



Getting to know your treatment

If you've been prescribed Avmapki Fakzynja Co-Pack for your *KRAS*-mutated recurrent LGSOC, this brochure can provide information to help you feel empowered as you prepare for your treatment journey ahead.

Remember that your healthcare provider is your trusted source of information every step of the way.



Stay connected

Sign up for email updates to receive helpful information and resources

A closer look at the treatment journey

Let's walk through important aspects of the treatment journey with Avmapki Fakzynja Co-Pack. On the following pages, you will find information in the order of topics below.



Before treatment

- Verastem Cares™ support program enrollment
- Guidance on access and resources



Preparing for treatment

- Details about your medical history
- Eye exams
- Tests/lab work



Starting with the first dose

- The dosing schedule
- Ways to help stay on track with dosing



Understanding important safety information

- Side effects that may occur
- Preventative medicines
- How side effects may be managed



Treatment adjustments

- Dosing modifications for side effects



Safety monitoring

- Eye exams
- Skin reactions
- Liver function tests
- Muscle function (CPK) tests



Reminders

- Making the most of your treatment

CPK, creatine phosphokinase.

Get help with access and support today

Before you start Avmapki Fakzynja Co-Pack, an important step is ensuring you have access to treatment as soon as possible.

Verastem Cares™

Our access and support program is designed to help both you and your healthcare provider navigate the process of starting Avmapki Fakzynja Co-Pack. Regardless of what insurance you have, or if you have no insurance at all, Verastem Cares™ has programs to support you.

Here are highlights of the program:



Commercial insurance

The Verastem Copay Program may cover your Avmapki Fakzynja Co-Pack out-of-pocket costs—pay as little as \$0.*



Medicare, Medicaid, or military insurance

We can refer you to independent foundations and organizations that may help with medication costs and offer other resources.



No insurance or underinsured for Avmapki Fakzynja Co-Pack?

If you are uninsured or your health plan doesn't cover Avmapki Fakzynja Co-Pack, you may still qualify for free medication options.†



Insurance-related delays in treatment?

If insurance-related delays are keeping you from initiating therapy or risking therapy interruption, you may be eligible for a free temporary supply of Avmapki Fakzynja Co-Pack while your healthcare provider works through the insurance issues.

*Copay program is subject to an annual benefit maximum.

†Patient Assistance Program eligibility rules apply.

Please see additional Important Safety Information throughout this brochure and discuss with your doctor.

 **AVMAPKI™ FAKZYNJA™ CO-PACK**
(avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg



At the time you are prescribed Avmapki Fakzynja Co-Pack or soon after, make sure your healthcare provider enrolls you in [Verastem Cares™](#)



Our dedicated team is ready to help

For more information and helpful resources on access and support, call today

866-351-8372

8:00AM to 8:00PM ET Monday-Friday

Please see additional Important Safety Information throughout this brochure and discuss with your doctor.

 **AVMAPKI™ FAKZYNJA™ CO-PACK**
(avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg



Planning ahead for your treatment

Before taking Avmapki Fakzynja Co-Pack, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of eye or vision problems
- have had severe skin reactions
- have liver problems
- are pregnant or plan to become pregnant. Avmapki Fakzynja Co-Pack can harm your unborn baby.
 - **Females who are able to become pregnant:**
 - Your healthcare provider should do a pregnancy test before you start treatment with Avmapki Fakzynja Co-Pack.
 - You should use effective birth control (contraception) during treatment and for 1 month after the last dose of Avmapki Fakzynja Co-Pack.
 - Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Avmapki Fakzynja Co-Pack.
 - **Males with a female partner who is able to become pregnant:**
 - You should use effective birth control (contraception) during treatment and for 4 months after the last dose of Avmapki Fakzynja Co-Pack.
- are breastfeeding or plan to breastfeed. It is not known if Avmapki Fakzynja Co-Pack passes into your breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Avmapki Fakzynja Co-Pack.

Planning ahead for your treatment

Tell your healthcare provider about all the medicines you take, including:

- prescription and over-the-counter medicines, vitamins, and herbal supplements. Avmapki Fakzynja Co-Pack may affect the way other medicines work, and other medicines may affect how Avmapki Fakzynja Co-Pack works.

Especially tell your healthcare provider if you take:

- proton pump inhibitors (PPIs) and H2 receptor antagonists*
- a blood thinner called warfarin



Know the medicines you take. Keep a list of them with you to show your healthcare provider and pharmacist when you get a new medicine.



*A PPI or an H2 receptor antagonist is a medicine that reduces the amount of acid the stomach makes. It helps relieve symptoms, such as acid reflux, heartburn, or indigestion.



Before your first dose

Preparing to start treatment with Avmapki Fakzynja Co-Pack will require tests to establish a baseline of your health status because Avmapki Fakzynja Co-Pack may cause serious side effects. While on treatment, your healthcare provider will refer to your baseline measurements as a reference point to see how you are tolerating treatment and if you are possibly experiencing any other health status changes.

Baseline tests/lab work needed before starting treatment:

- Eye exam with an eye care professional
- Blood test to check your liver function
- Blood test to check your levels of CPK*
- Pregnancy test

*A blood test that measures the level of an enzyme called creatine phosphokinase (CPK) needed for your muscles to work properly.

Please see additional Important Safety Information throughout this brochure and discuss with your doctor.

 **AVMAPKI™ FAKZYNJA™ CO-PACK**
(avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg

Get to know the dosing schedule

Take some time to understand the dosing schedule upfront so you can make it part of your routine.

- Take Avmapki Fakzynja Co-Pack exactly as directed by your healthcare provider
- Do not change your dose or stop taking Avmapki Fakzynja Co-Pack without talking to your healthcare provider
- If you develop certain side effects, your healthcare provider may change your dose, temporarily stop, or completely stop your treatment with Avmapki Fakzynja Co-Pack
- If you vomit after taking Avmapki capsules or Fakzynja tablets, do not take an additional dose. Take the next scheduled dose as prescribed by your healthcare provider
- If you miss a dose of Avmapki by more than 24 hours, skip the missed dose and take the next scheduled dose as prescribed by your healthcare provider. Do not take two doses at the same time to make up for a missed dose
- If you miss a dose of Fakzynja by more than 6 hours, skip the missed dose and take the next scheduled dose as prescribed by your healthcare provider. Do not take two doses at the same time to make up for a missed dose



Avmapki Fakzynja Co-Pack is an oral combination treatment



Avmapki

Fakzynja

Notice how the Avmapki capsule and Fakzynja tablet look different.

Product images shown are not actual size.

Please see additional Important Safety Information throughout this brochure and discuss with your doctor.

 **AVMAPKI™ FAKZYNJA™ CO-PACK**
(avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg

Get to know the dosing schedule (cont'd)

The dosing schedule is based on a 4-week cycle.
Avmapki Fakzynja Co-Pack is taken during **the first 3 weeks**.

Take your medication orally (by mouth) as follows:

Avmapki



3.2 mg (4 capsules) = 1 DOSE

- On **Weeks 1, 2, and 3**, take 3.2 mg (4 capsules) on **Day 1** and **Day 4**
- Take each dose at the same time **with food**
- Swallow the capsules whole. Do not chew, break, or open the capsules

Fakzynja



200 mg (1 tablet) = 1 DOSE

- On **Weeks 1, 2, and 3**, take 200 mg (1 tablet) **2 times a day**
- Take **with food**
- Swallow the tablets whole. Do not chew, break, or crush the tablets

















Keep the medications refrigerated between 36°F and 46°F (2°C to 8°C) in the original bottles

Week 4

Take a 1-week break from medication

This completes 1 treatment cycle

Avmapki | Fakzynja

	Time	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
Weeks 1, 2, & 3	Morning Same Time	 + 			 + 			
	Evening							
Week 4	ONE-WEEK BREAK. Do not take Avmapki Fakzynja Co-Pack during Week 4.							

Product images shown are not actual size.

Please see additional Important Safety Information throughout this brochure and discuss with your doctor.

 **AVMAPKI™ FAKZYNJA™ CO-PACK**
(avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg



Ways to help stay on track with dosing



[Watch the Dosing Video](#)

Learn more about how to take Avmapki Fakzynja Co-Pack along with tips and recommendations



[Download the Dosing Calendar](#)

The Dosing Calendar features the 28-day cycle with boxes to check off each dose. When you are ready to start the next cycle, print out another calendar.



If you need a reminder when to take your dose, you can set an alarm on your phone.

Please see additional Important Safety Information throughout this brochure and discuss with your doctor.

 **AVMAPKI™ FAKZYNJA™ CO-PACK**
(avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg

Understanding important safety information

There are side effects that can occur while taking Avmapki Fakzynja Co-Pack. It's important to be aware of safety considerations—and to **inform your healthcare provider of any side effects or concerns as soon as possible.**

Avmapki Fakzynja Co-Pack may cause serious side effects, including eye problems, severe skin reactions, liver problems, and muscle problems such as rhabdomyolysis. These are not all the possible side effects of Avmapki Fakzynja Co-Pack. Speak to your healthcare provider for medical advice about side effects.

With guidance from their healthcare providers, 84% of women saw resolution of side effects with dose interruptions and 44% of women with dose reductions, while 14% of women discontinued treatment.



[Download the Side Effects Information Card](#)

Learn about how your healthcare provider may monitor for and manage possible side effects. Refer to it during your treatment journey.

Understanding important safety information (cont'd)

Before and during treatment, your healthcare provider will give you:



Corticosteroid medicine to apply to your face, scalp, neck, upper chest, and upper back



Antibiotic medicines to take by mouth

The use of these medications to prevent skin reactions is recommended.

Start using them in advance of your first dose of Avmapki Fakzynja Co-Pack and continue taking them during treatment according to your healthcare provider's instructions.



Limit your time in the sun

Avmapki Fakzynja Co-Pack can make your skin sensitive to the sun and the light from sunlamps and tanning beds

- You may burn more easily and get a severe sunburn
- Be sure to apply daily sunscreen with a sun protection factor (SPF) of 30 or more
- Wear a hat and clothes that cover your skin to protect against sunburn
- Tell your healthcare provider if you get a sunburn



Avmapki Fakzynja Co-Pack may cause serious side effects including eye problems

Eye problems are common with Avmapki Fakzynja Co-Pack and can be severe. Your healthcare provider will send you to an eye care professional before and during treatment, and for any new or worsening eye problems, even if there are no initial findings.

Tell your healthcare provider if you get any new or worsening eye problems, including:

- changes in vision, such as blurred vision, double vision, or vision loss
- dry eye(s)
- eye and eyelid inflammation, including redness, swelling, and itching
- eye pain
- new or increased floaters (small dark spots or squiggly lines that float across your vision)
- light hurting eyes or seeing flashes of light

The most common treatment-related eye problems were changes in vision (38%), such as blurred vision, which were typically mild to moderate in severity.

Please see additional Important Safety Information throughout this brochure and discuss with your doctor.

 **AVMAPKI™ FAKZYNJA™ CO-PACK**
(avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg



Understanding important safety information (cont'd)

Avmapki Fakzynja Co-Pack may cause serious side effects, including:

Severe skin reactions. Skin reactions are common with Avmapki Fakzynja Co-Pack and can be severe or life threatening.

Tell your healthcare provider if you develop any new or worsening skin reactions, including:

- skin rash or acne
- dry skin
- itching
- blisters on your skin
- redness or swelling of your face, hands, or soles of your feet
- blisters or sores in your mouth
- peeling of your skin
- skin infection

Liver problems. Liver problems are common with Avmapki Fakzynja Co-Pack and can be severe. Treatment with Avmapki Fakzynja Co-Pack can increase the level of

aspartate aminotransferase, alanine aminotransferase, and bilirubin in your blood. Your healthcare provider will do blood tests before starting each treatment cycle and during treatment to check your liver function.

Tell your healthcare provider if you get any signs or symptoms of severe liver problems including:

- yellowing of your skin or the white part of your eyes
- itchy skin
- feeling very tired
- flu-like symptoms
- nausea or vomiting
- upper right side stomach pain
- dark or tea colored urine
- bleeding or bruising more easily than normal

Understanding important safety information (cont'd)

Avmapki Fakzynja Co-Pack may cause serious side effects, including: (cont'd)

Muscle problems (rhabdomyolysis). Avmapki Fakzynja Co-Pack may cause muscle problems that can be severe. Treatment with Avmapki Fakzynja Co-Pack can increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Your healthcare provider will perform blood tests to check your levels of CPK before starting each treatment cycle and during treatment.

Tell your healthcare provider if you get any signs or symptoms of increased CPK including:

- weakness or difficulty moving arms and legs
- muscle or bone aches or pain that does not go away
- dark, red colored urine or decreased urine output

Be aware of the most common side effects of Avmapki Fakzynja Co-Pack, which include:

- nausea
- tiredness
- increased aspartate aminotransferase
- diarrhea
- swelling in the body (edema)
- decreased hemoglobin
- increased alanine aminotransferase
- vomiting
- increased blood bilirubin
- increased triglycerides
- stomach-area pain
- acid reflux
- increased alkaline phosphatase
- decreased platelets
- constipation
- shortness of breath
- cough
- urinary tract infection
- decreased lymphocytes
- decreased neutrophils
- proteinuria

The most common side effects of Avmapki Fakzynja Co-Pack were mild to moderate in severity, with 14% of women experiencing side effects that caused them to stop treatment.

Understanding important safety information (cont'd)

Avmapki Fakzynja Co-Pack may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of Avmapki Fakzynja Co-Pack. Call your healthcare provider for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

When side effects require changes in dosing

If you experience certain side effects, your healthcare provider may reduce the dose you are taking of Avmapki Fakzynja Co-Pack in an effort to make the side effect(s) manageable while allowing you to stay on treatment.

Be sure to discuss exactly how to proceed with your modified dosing schedule with your healthcare provider.

If your treatment plan requires dosing modifications, you can use the Reduced Dosage Dosing Calendar print-out to help you stay on track. It features the 28-day cycle with boxes to check off each dose after you take it.



[Download the Reduced Dosage Dosing Calendar](#)





Safety monitoring during treatment

Your healthcare team will be observing your treatment response with the help of **routine exams, lab tests, and check-ins**

Eye exams	at baseline, prior to cycle 2, and every 3 cycles thereafter, regardless of baseline exam findings, and as determined by your healthcare provider
Skin reaction assessments	throughout treatment
Liver function tests	prior to each cycle, on day 15 of the first 4 cycles, and as determined by your healthcare provider
Muscle function (CPK) tests	prior to the start of each cycle, on day 15 of the first 4 cycles, and as determined by your healthcare provider

Ongoing monitoring can help your healthcare provider determine if you may need any modifications to your treatment plan, including a reduced dosing schedule, dose interruption, or permanent discontinuation.

Reminders

Making the most of your treatment



Follow the guidance of your healthcare provider



Stay on top of your dosing schedule. Use the available dosing resources



Play a role in your safety by understanding the important safety information. See page 12 to download the Side Effects Information Card and follow up with your healthcare provider as needed



Follow any treatment adjustments recommended by your healthcare provider



Attend scheduled healthcare provider and lab work appointments



Stay connected—your care team, loved ones, and support groups are there for you



Download the Treatment Tracker

Use this tool to track your possible side effects and discuss them with your healthcare provider.

REIMAGINE WHAT'S POSSIBLE

Access additional resources available to help you every step of the way



Scan QR code or visit
www.AvmapkiFakzynjaCo-Pack.com



Our dedicated team is ready to help

For more information and helpful resources on access and support

Call today **866-351-8372**

8:00AM to 8:00PM ET Monday-Friday



Please see Important Safety Information throughout this brochure and discuss with your doctor. Click here for full [Prescribing Information](#) and [Patient Information](#).

©2026 Verastem, Inc. All Rights Reserved. AF-US-2025-0192 03/26
Avmapki and Fakzynja are trademarks of Verastem, Inc.
Verastem Cares is a trademark of Verastem, Inc.
For US patients and caregivers 18 years of age or older.

 **AVMAPKI™ FAKZYNJA™ CO-PACK**
(avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg